Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor-resistant ...
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...
TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 ...
Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment. Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast ...
and Daiichi Sankyo is attempting to gain approval for its ADC patritumab deruxtecan. AstraZeneca, which also has a cancer drug partnership with Daiichi, markets Imfinzi and Tagrisso for several ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback